722 related articles for article (PubMed ID: 8481913)
21. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
22. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
23. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the inflammatory cytokines in the vagina during pregnancy and labor and with bacterial vaginosis.
Imseis HM; Greig PC; Livengood CH; Shunior E; Durda P; Erikson M
J Soc Gynecol Investig; 1997; 4(2):90-4. PubMed ID: 9101468
[TBL] [Abstract][Full Text] [Related]
25. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
27. Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.
Stasi R; Conforti M; Del Poeta G; Simone MD; Coppetelli U; Tribalto M; Cantonetti M; Perrotti A; Venditti A; Papa G
Haematologica; 1992; 77(6):518-21. PubMed ID: 1289190
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
[TBL] [Abstract][Full Text] [Related]
30. Serum and urine levels of interleukin-8 in patients with non-Hodgkin's lymphoma.
Lee HL; Eom HS; Yun T; Kim HJ; Park WS; Nam BH; Moon-Woo S; Lee DH; Kong SY
Cytokine; 2008 Jul; 43(1):71-5. PubMed ID: 18502145
[TBL] [Abstract][Full Text] [Related]
31. Cost determinants in aggressive non-Hodgkin's lymphoma.
van Agthoven M; Sonneveld P; Verdonck LF; Uyl-de Groot CA
Haematologica; 2005 May; 90(5):661-71. PubMed ID: 15921381
[TBL] [Abstract][Full Text] [Related]
32. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
34. High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
Salgami EV; Efstathiou SP; Vlachakis V; Sekara EV; Syrigos KN; Roussou PP
Haematologia (Budap); 2002; 32(4):377-87. PubMed ID: 12803112
[TBL] [Abstract][Full Text] [Related]
35. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
[TBL] [Abstract][Full Text] [Related]
36. Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.
Krugmann J; Tzankov A; Gschwendtner A; Fischhofer M; Greil R; Fend F; Dirnhofer S
Mod Pathol; 2003 Jun; 16(6):566-73. PubMed ID: 12808062
[TBL] [Abstract][Full Text] [Related]
37. Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus.
Robak E; Robak T; Wozniacka A; Zak-Prelich M; Sysa-Jedrzejowska A; Stepien H
Eur Cytokine Netw; 2002; 13(3):364-8. PubMed ID: 12231481
[TBL] [Abstract][Full Text] [Related]
38. [Immunohistochemical in situ demonstration of cytokines in Hodgkin and non-Hodgkin lymphoma].
Müller H; Takeshita M; Krause J; Schuster K; Kikuchi M; Stutte HJ
Verh Dtsch Ges Pathol; 1992; 76():164-8. PubMed ID: 1283251
[TBL] [Abstract][Full Text] [Related]
39. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
[TBL] [Abstract][Full Text] [Related]
40. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma.
Pedersen LM; Klausen TW; Davidsen UH; Johnsen HE
Ann Hematol; 2005 Aug; 84(8):510-6. PubMed ID: 15834569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
